미국의 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 약제별, 서비스별, 치료 분야별, 최종 용도별, 부문 예측, 2025년-203년

U.S. Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Drug, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 203

US $ 5,950 ￦ 8,323,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,722,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,520,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

시장 규모 및 동향

미국의 신약개발 아웃소싱 시장 규모는 2024년 24억 9,000만 달러로 추정되며, 2025-2033년 연평균 9.52% 성장할 것으로 예측됩니다.

신약 후보물질에 대한 수요 증가, 만성질환 유병률 증가, R&D 비용 증가, 새로운 민관 파트너십 구축, 전문 지식의 필요성, 복잡한 표적치료제 증가 등이 신약개발 아웃소싱 시장을 주도하고 있습니다.

또한, 많은 바이오제약 및 제약기업들은 인공지능, 바이오인포매틱스, 고성능 스크리닝 등 첨단 기술을 활용하기 위해 CRO 및 CDMO를 이용하고 있습니다. 또한, 사내에 탄탄한 역량을 갖추지 못한 소규모 가상 생명공학 기업들이 증가하고 있는 것도 아웃소싱의 추세를 더욱 가속화시키고 있습니다.

또한, 개인 맞춤형 의료 및 적응형 개발 프레임워크로의 전환 추세도 신약개발 서비스 아웃소싱 수요를 증가시키고 있습니다. 세계화, IND 신청 기간 단축의 필요성, 새로운 치료 영역의 출현은 아웃소싱을 성장을 위한 중요한 전략으로 지속적으로 밀어붙이고 있습니다.

또한, 개인 맞춤형 의료의 부상으로 인해 미국 신약개발 아웃소싱 부문에서 적응성이 높은 소량 생산의 필요성이 높아지고 있습니다. 특히 종양학, 희귀질환, 유전자 치료 등의 분야에서 치료의 타겟이 좁혀짐에 따라 기존의 대량 생산 방식은 맞춤형 의약품 개발 전략으로 전환되고 있으며, 이는 추정 기간 동안 시장 성장을 가속할 것으로 예측됩니다.

개발수탁기관(CRO) 및 연구개발수탁기관(CDRO)은 모듈화된 인프라, 유연한 워크플로우, 신속한 분석법 개발을 활용하여 중요한 파트너가 되고 있습니다. 아웃소싱을 통해 바이오 제약사는 약물 설계, 환자군 분류, 바이오마커 기반 연구에서의 편차를 조정할 수 있는 역량을 확보할 수 있으며, 이를 통해 정밀한 치료제 시장 출시에 있어 민첩성, 비용 효율성 및 속도를 향상시킬 수 있습니다.

또한, 인공지능(AI)과 머신러닝(ML)의 통합은 신약개발에 있어 화합물 식별, 최적화 및 검증 과정을 변화시키고 있습니다. AI는 표적 식별을 간소화하고, 약물 유사성을 평가하고, 분자 간 상호 작용을 모델링함으로써 초기 단계의 연구개발 일정과 비용을 크게 줄일 수 있습니다. 또한, ML 알고리즘은 오믹스 데이터에서 임상 결과까지 광범위한 데이터 세트를 선별하여 혁신적인 통찰력을 제공하고, 후보 화합물 선택에 대한 위험을 최소화합니다.

또한, 미국 바이오 제약사들은 생산성을 높이고, 임상시험계획(IND) 신청까지의 과정을 가속화하며, 복잡한 질환 및 희귀질환 치료제의 개발 성공률을 높이기 위해 AI를 활용한 솔루션을 워크플로우에 도입하거나, AI 전문 CRO(임상시험수탁기관)와 협력하고 있습니다. 하는 움직임이 가속화되고 있습니다. 예를 들어, 2024년 7월 Exscientia plc는 클라우드 제공업체의 AI 및 ML 서비스를 활용하여 엔드투엔드 신약개발 및 자동화를 위한 자사의 플랫폼을 강화하기 위해 Amazon Web Services의 확장을 언급했습니다. 이러한 요인들이 추정 기간을 견인할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 Drug Discovery 아웃소싱 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 임상 검사 건수 분석(2024년)
  • 지역별 임상시험 건수
  • 임상시험 건수(상별)
  • 임상시험 건수(연구 디자인별)
  • 주요 치료 영역별 임상시험 건수
• 가격 모델 분석
• 기술
• 시장 분석 툴
  • Porter의 Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 미국의 Drug Discovery 아웃소싱 시장 : 워크플로우별, 추정·동향 분석

• 미국의 Drug Discovery 아웃소싱 시장(워크플로우별) : 부문 대시보드
• 미국의 Drug Discovery 아웃소싱 시장(워크플로우별) : 변동 분석
• 워크플로우별, 2021-2033년
• 대상 특정 및 스크리닝
• 대상 검증 및 기능 정보과학
• 리드 특정 및 후보자 최적화
• 전임상 개발
• 기타

제5장 미국의 Drug Discovery 아웃소싱 시장 : 약제별, 추정·동향 분석

• 미국의 Drug Discovery 아웃소싱 시장(약제별) : 부문 대시보드
• 미국의 Drug Discovery 아웃소싱 시장(약제별) : 변동 분석
• 약제별, 2021-2033년
• 소분자
• 거대 분자

제6장 미국의 Drug Discovery 아웃소싱 시장 : 서비스별, 추정·동향 분석

• 미국의 Drug Discovery 아웃소싱 시장(서비스별) : 부문 대시보드
• 미국의 Drug Discovery 아웃소싱 시장(서비스별) : 변동 분석
• 서비스별, 2021-2033년
• 화학 서비스
• 생물 서비스

제7장 미국의 Drug Discovery 아웃소싱 시장 : 치료 분야별, 추정·동향 분석

• 미국의 Drug Discovery 아웃소싱 시장(치료 분야별) : 부문 대시보드
• 미국의 Drug Discovery 아웃소싱 시장(치료 분야별) : 변동 분석
• 치료 분야별, 2021-2033년
• 호흡기
• 통증과 마취
• 종양학
• 안과
• 혈액학
• 심혈관계
• 내분비
• 위장
• 면역 조절
• 항감염성
• 중추신경계
• 피부과
• 비뇨생식기계

제8장 미국의 Drug Discovery 아웃소싱 시장 : 최종 용도별, 추정·동향 분석

• 미국의 Drug Discovery 아웃소싱 시장(최종 용도별) : 부문 대시보드
• 미국의 Drug Discovery 아웃소싱 시장(최종 용도별) : 변동 분석
• 최종 용도별, 2021-2033년
• 제약 바이오테크놀러지 기업
• 학술기관

제9장 경쟁 구도

• 시장 진출기업 분류
• 기업의 시장 점유율/평가 분석, 2024년
• 기업 개요
  • Albany Molecular Research Inc.
  • EVOTEC
  • Laboratory Corporation of America Holdings
  • GenScript
  • Pharmaceutical Product Development, LLC
  • Charles River Laboratories
  • WuXi AppTec
  • Thermo Fisher Scientific Inc.
  • Dalton Pharma Services
  • Oncodesign
  • Jubilant Biosys
  • DiscoverX Corp.
  • QIAGEN
  • Eurofins SE
  • Syngene International Limited
  • Dr. Reddy Laboratories Ltd.
  • Pharmaron Beijing Co., Ltd.
  • TCG Lifesciences Pvt Ltd.
  • Domainex Ltd.

제10장 주요 추천 사항

LSH

영문 목차

영문목차

Market Size & Trends:

The U.S. drug discovery outsourcing market size was estimated at USD 2.49 billion in 2024 and is projected to grow at a CAGR of 9.52% from 2025 to 2033. The market for drug discovery outsourcing is driven by growing demand for novel drug candidates, rising incidence of chronic diseases, increasing R&D expenditures, emerging new private-public partnerships, a need for specialized knowledge, and a growing array of complex and targeted therapies.

Besides, most of the biopharmaceutical and pharmaceutical companies are turning to CROs and CDMOs to leverage advanced technologies such as artificial intelligence, bioinformatics, and high-throughput screening. In addition, the rising number of small and virtual biotech companies, which often lack robust internal capabilities, further accelerates the trend toward outsourcing.

Moreover, shifting trends towards personalized medicine and adaptable development frameworks enhances the demand for outsourced discovery services. Globalization, the need for quicker time-to-IND submissions, and the emergence of new therapeutic areas are continuously driving outsourcing as a key strategy for growth.

In addition, the emergence of personalized medicine is driving the need for adaptable, small-batch production within the U.S. drug discovery outsourcing sector. As treatments become increasingly targeted, particularly in areas like oncology, rare diseases, and gene therapy, traditional mass production methods are shifting towards customized drug development strategies, which are expected to drive the market growth over the estimated time period.

Contract research organizations (CROs) and contract development and research organizations (CDROs) utilize a modular infrastructure, flexible workflows, and quick assay development are becoming vital partners. Outsourcing provides biopharma companies with the ability to navigate variability in drug design, patient stratification, and biomarker-driven studies, which in turn enhances their agility, cost-effectiveness, and speed in bringing precision therapies to market.

Furthermore, the growing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the process of identifying, optimizing, and validating compounds. AI streamlines target identification, assesses drug-likeness, and models molecular interactions, leading to significant reductions in early-stage R&D timelines and expenses. Besides, ML algorithms sift through extensive datasets ranging from omics data to clinical outcomes to reveal innovative insights and minimize risks in candidate selection.

In addition, biopharma companies in the U.S. are increasingly incorporating AI-driven solutions into their workflows or collaborating with AI-focused contract research organizations (CROs) to boost productivity, accelerate the path to Investigational New Drug (IND) applications, and enhance success rates in the development of treatments for complex and rare diseases. For instance, in July 2024, Exscientia plc mentioned Amazon Web Services expansion to use the AI & ML services of cloud providers to power the company's platform for end-to-end drug discovery and automation. Such factors are expected to drive the estimated time period.

U.S. Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. drug discovery outsourcing market report based on workflow, drug, service, therapeutics area, end use, and country.

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecules
• Large Molecules
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Chemistry Services
• Biology Services
• Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology companies
• Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Drug
  • 1.2.3. Service
  • 1.2.4. Therapeutics Area
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Value chain-based analysis
  • 1.7.3. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising R&D cost in biopharmaceutical Industry
    • 3.2.1.2. Increasing access to specialized expertise
    • 3.2.1.3. Growing demand for outsourcing Services in Drug Development
    • 3.2.1.4. Increasing number of partnerships in U.S. Drug Discovery research
    • 3.2.1.5. Technological advancements in drug discovery
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of open-source software packages for drug discovery
    • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
    • 3.2.2.3. Rising Data Security and IP Concerns
    • 3.2.2.4. Regulatory and Compliance Risks
• 3.3. Clinical Trials Volume Analysis (2024)
  • 3.3.1. Total Number of Clinical Trials, By Region
  • 3.3.2. Total Number of Clinical Trials, By Phase
  • 3.3.3. Total Number of Clinical Trials, By Study Design
  • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
• 3.4. Pricing Model Analysis
• 3.5. Technology Landscape
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. U.S. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
• 4.2. U.S. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
• 4.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

• 5.1. U.S. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
• 5.2. U.S. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
• 5.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
• 5.4. Small Molecules
  • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Large Molecules
  • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

• 6.1. U.S. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
• 6.2. U.S. Drug Discovery Outsourcing Market, By Service: Movement Analysis
• 6.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Chemistry Services
  • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biology Services
  • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

• 7.1. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
• 7.2. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
• 7.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
• 7.4. Respiratory system
  • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Pain and Anesthesia
  • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Oncology
  • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Ophthalmology
  • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Hematology
  • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Cardiovascular
  • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Endocrine
  • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.11. Gastrointestinal
  • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.12. Immunomodulation
  • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.13. Anti-infective
  • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.14. Central Nervous System
  • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.15. Dermatology
  • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.16. Genitourinary System
  • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. U.S. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
• 8.2. U.S. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
• 8.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Pharmaceutical & Biotechnology companies
  • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Academic Institutes
  • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Albany Molecular Research Inc.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. EVOTEC
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Laboratory Corporation of America Holdings
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. GenScript
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Pharmaceutical Product Development, LLC
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Charles River Laboratories
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. WuXi AppTec
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Thermo Fisher Scientific Inc.
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Dalton Pharma Services
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Oncodesign
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Jubilant Biosys
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. DiscoverX Corp.
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. QIAGEN
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Eurofins SE
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Syngene International Limited
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Dr. Reddy Laboratories Ltd.
    • 9.3.16.1. Company Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Service Benchmarking
    • 9.3.16.4. Strategic Initiatives
  • 9.3.17. Pharmaron Beijing Co., Ltd.
    • 9.3.17.1. Company Overview
    • 9.3.17.2. Financial Performance
    • 9.3.17.3. Service Benchmarking
    • 9.3.17.4. Strategic Initiatives
  • 9.3.18. TCG Lifesciences Pvt Ltd.
    • 9.3.18.1. Company Overview
    • 9.3.18.2. Financial Performance
    • 9.3.18.3. Service Benchmarking
    • 9.3.18.4. Strategic Initiatives
  • 9.3.19. Domainex Ltd.
    • 9.3.19.1. Company Overview
    • 9.3.19.2. Financial Performance
    • 9.3.19.3. Service Benchmarking
    • 9.3.19.4. Strategic Initiatives

Chapter 10. Key Recommendations

관련자료